ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression

O. Pankewycz1, M. Laftavi1, E. Onan2, D. Rucker1, D. Wang1, K. Bhuta1, R. Gruessner3, A. Gruessner3

1SUNY, Upstate Medical University, Syracuse, NY, 2Cukurova University, Adana, Turkey, 3SUNY, Downstate Medical University, New York, NY

Meeting: 2020 American Transplant Congress

Abstract number: B-311

Keywords: Area-under-curve (AUC), Dosage, Kidney transplantation, Mycophenolate mofetil

Session Information

Session Name: Poster Session B: Biomarkers, Immune Assessment and Clinical Outcomes

Session Type: Poster Session

Date: Saturday, May 30, 2020

Session Time: 3:15pm-4:00pm

 Presentation Time: 3:30pm-4:00pm

Location: Virtual

*Purpose: Tacrolimus (TAC) and mycophenolic acid (MPA) remain the most commonly used drug combination for kidney transplant immunosuppression. Adequate drug dosing is challenging due to the lack of a reliable method of assessing optimal drug exposure. Therapeutic drug monitoring (TDM) for TAC is well established. However, the value of TDM for MPA remains unclear. We evaluated the value of combining time integrated trough TAC levels and MPA exposure in predicting clinical outcomes.

*Methods: This retrospective single center study included 110 renal transplant recipients having 113 separate events treated with TAC and mycophenolate mofetil (MMF). MPA and MPA-G AUC were measured by limited sampling strategy within the first 6 months post-transplant. Outcomes over the first year were collected and analyzed.

*Results: Patients were classified into 3 groups: Stable (n=34) having an uncomplicated course, Over drug exposed (n=64) experiencing viral infections or drug toxicity and Under drug exposed (n=15) developing rejection or dnDSA. The groups had similar demographics . Although TAC, MPA and MPA-G exposure differed between groups the individual values were either not predictive or had exceedingly narrow ranges to be clinically useful. Combining the TAC, MPA and MPA-G exposure into one calculation the Combined Formula: TAC TDM X (MPA AUC + MPA-G AUC/10) provided the greatest separation between groups and identifies both over and under drug exposed patients (Figure 1). The ROC curves for the Combined Formula had AUC values of 0.77 and 0.92 for under and over drug exposure respectively. The sensitivity and specificity of a Combined Formula score of 1,071 for over exposure is 0.94 (95% CI 0.56-0.83) and 0.84 (95% CI 0.69-0.89) respectively. For under exposure a score of 625 has a sensitivity and specificity of 0.76 (95% CI 0.53-0.93) and 0.80 (95% CI 0.41-0.70) (Figure 2).

*Conclusions: This practical and more reliable method to assess overall tacrolimus and MPA effect may facilitate individualized immunosuppression.

 border=

 border=

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

To cite this abstract in AMA style:

Pankewycz O, Laftavi M, Onan E, Rucker D, Wang D, Bhuta K, Gruessner R, Gruessner A. A Novel Formula to Determine Optimal Immunosuppression in Renal Transplant Recipients Treated with Tacrolimus and Mycophenolate Mofetil: Towards Individualized Immunosuppression [abstract]. Am J Transplant. 2020; 20 (suppl 3). https://atcmeetingabstracts.com/abstract/a-novel-formula-to-determine-optimal-immunosuppression-in-renal-transplant-recipients-treated-with-tacrolimus-and-mycophenolate-mofetil-towards-individualized-immunosuppression/. Accessed May 16, 2025.

« Back to 2020 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences